RESUMEN
In Covid-19, systemic disturbances may progress due to development of cytokine storm and dysregulation of and plasma osmolarility due to high release of pro-inflammatory cytokines and neuro-hormonal disorders. Arginine vasopressin (AVP) which is involve in the regulation of body osmotic system, body water content, blood pressure and plasma volume, that are highly disturbed in Covid-19 and linked with poor clinical outcomes. Therefore, this present study aimed to find the potential association between AVP serum level and inflammatory disorders in Covid-19. It has been observed by different recent studies that physiological response due to fever, pain, hypovolemia, dehydration, and psychological stress is characterized by activation release of AVP to counter-balance high blood viscosity in Covid-19 patients. In addition, activated immune cells mainly T and B lymphocytes and released pro-inflammatory cytokines stimulate discharge of stored AVP from immune cells, which in a vicious cycle trigger release of pro-inflammatory cytokines. Vasopressin receptor antagonists have antiviral and anti-inflammatory effects that may inhibit AVP-induced hyponatremia and release of pro-inflammatory cytokines in Covid-19. In conclusion, release of AVP from hypothalamus is augmented in Covid-19 due to stress, high pro-inflammatory cytokines, high circulating AngII and inhibition of GABAergic neurons. In turn, high AVP level leads to induction of hyponatremia, inflammatory disorders, and development of complications in Covid-19 by activation of NF-κB and NLRP3 inflammasome with release of pro-inflammatory cytokines. Therefore, AVP antagonists might be novel potential therapeutic modality in treating Covid-19 through mitigation of AVP-mediated inflammatory disorders and hyponatremia.
Asunto(s)
Arginina Vasopresina , Tratamiento Farmacológico de COVID-19 , COVID-19 , Arginina Vasopresina/antagonistas & inhibidores , Arginina Vasopresina/metabolismo , COVID-19/inmunología , COVID-19/metabolismo , Descubrimiento de Drogas , Humanos , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , SARS-CoV-2 , Desequilibrio Hidroelectrolítico/tratamiento farmacológicoRESUMEN
La oxitocina (OXT) como la arginina-vasopresina (AVP) son dos hormonas primitivas secretadas por la hipófisis posterior. Sus receptores están mucho más ampliamente distribuidos en el organismo de lo que se pensaba originalmente, incluido el hueso. En los estudios preclínicos, la OXT ha mostrado ser anabólica para el hueso, promoviendo la osteogénesis sobre la adipogénesis y favoreciendo la actividad osteoblástica sobre la osteoclástica. Tanto los osteoblastos como los osteoclastos tienen receptores para la OXT, y los efectos de los estrógenos sobre la masa ósea en ratones está mediada por lo menos en parte por la OXT. El mecanismo preciso por el cual la activación de los receptores de oxitocina (OXTR) se traduce en un incremento de la formación ósea permanece poco claro. La AVP también podría afectar el esqueleto en forma directa. Dos de los receptores de la AVP, V1a y V2 están expresados en osteoblastos y osteoclastos. La inyección de AVP en ratones de tipo salvaje aumenta la formación osteoclastos que producen resorción y reduce los osteoblastos formadores de hueso. En forma opuesta, la exposición de precursores osteoblásticos a antagonistas de los receptores V1a o V2, incrementan la osteoblastogénesis, como también lo hace la deleción genética del receptor V1a. (AU)
Both oxytocin (OXT) and argininevasopressin (AVP) are primitive hormones secreted by the posterior pituitary gland. OXT receptors are much more widely distributed in the body than originally thought, including in bone. In preclinical studies, OXT has been shown to be anabolic for bone, promoting osteogenesis over adipogenesis and favoring osteoblastic over osteoclastic activity. Both osteoblasts and osteoclasts have receptors for OXT, and the effects of estrogen on bone mass in mice is mediated at least in part by OXT. The precise mechanism by which the activation of oxytocin receptors (OXTRs) results in an increase in bone formation remains unclear. AVP could also have direct actions on the skeleton. The two AVP receptors, V1a and V2, are expressed in osteoblasts and osteoclasts. Injection of AVP in wild-type mice increases the formation of osteoclasts increasing bone resorption, and reduces bone-forming osteoblasts. On the contrary, the exposure of osteoblastic precursors to V1a and V2 antagonists increase osteoblastogenesis, the same as the genetic deletion of the V1a receptor. (AU)
Asunto(s)
Humanos , Animales , Ratones , Hormonas Neurohipofisarias/biosíntesis , Arginina Vasopresina/efectos adversos , Oxitocina/uso terapéutico , Osteoblastos/fisiología , Osteoclastos/fisiología , Osteogénesis , Osteoporosis/terapia , Hormonas Neurohipofisarias/fisiología , Arginina Vasopresina/antagonistas & inhibidores , Arginina Vasopresina/biosíntesis , Arginina Vasopresina/fisiología , Arginina Vasopresina/uso terapéutico , Oxitocina/biosíntesis , Oxitocina/efectos adversos , Oxitocina/fisiología , Transducción de Señal , Densidad Ósea , Densidad Ósea/efectos de los fármacos , Receptores de Oxitocina/biosíntesis , Receptores de Oxitocina/fisiología , Estradiol/uso terapéutico , Estrógenos/fisiologíaRESUMEN
BACKGROUND: Arginine vasopressin (VP) has been implicated in a number of neuropsychiatric disorders with an emphasis on situations where stress increased the severity of the disorder. Based on this hypothesized role for VP in neuropsychiatric disorders, much research is currently being undertaken in humans and animals to test VP as a target for treatment of a number of these disorders including alcohol abuse. OBJECTIVES: To provide a summary of the literature regarding the role of VP in alcohol- and stress-related behaviors including the use of drugs that target VP in clinical trials. RESULTS: Changes in various components of the VP system occur with alcohol and stress. Manipulating VP or its receptors can alter alcohol- and stress-related behaviors including tolerance to alcohol, alcohol drinking, and anxiety-like behavior. Finally, the hypothalamic-pituitary-adrenal axis response to alcohol is also altered by manipulating the VP system. However, clinical trials of VP antagonists have had mixed results. CONCLUSIONS: A review of VP's involvement in alcohol's actions demonstrates that there is much to be learned about brain regions involved in VP-mediated effects on behavior. Thus, future work should focus on elucidating relevant brain regions. By using previous knowledge of the actions of VP and determining the brain regions and/or systems involved in its different behavioral effects, it may be possible to identify a specific receptor subtype target, drug treatment combination, or specific clinical contexts that may point toward a more successful treatment.
Asunto(s)
Consumo de Bebidas Alcohólicas/metabolismo , Alcoholismo/metabolismo , Etanol/administración & dosificación , Neurofisinas/metabolismo , Precursores de Proteínas/metabolismo , Vasopresinas/metabolismo , Consumo de Bebidas Alcohólicas/tratamiento farmacológico , Consumo de Bebidas Alcohólicas/psicología , Alcoholismo/tratamiento farmacológico , Alcoholismo/psicología , Animales , Antagonistas de los Receptores de Hormonas Antidiuréticas/farmacología , Ansiedad/tratamiento farmacológico , Ansiedad/metabolismo , Ansiedad/psicología , Arginina Vasopresina/antagonistas & inhibidores , Arginina Vasopresina/metabolismo , Etanol/toxicidad , Humanos , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Sistema Hipotálamo-Hipofisario/metabolismo , Neurofisinas/antagonistas & inhibidores , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Sistema Hipófiso-Suprarrenal/metabolismo , Precursores de Proteínas/antagonistas & inhibidores , Estrés Psicológico/tratamiento farmacológico , Estrés Psicológico/metabolismo , Estrés Psicológico/psicología , Vasopresinas/antagonistas & inhibidoresRESUMEN
BACKGROUND: The association with opioid-abusing individuals or even the perception of opioid abuse by peers are risk factors for the initiation and escalation of abuse. Similarly, we demonstrated that morphine-treated animals housed with only morphine-treated animals (referred to as morphine only) acquire morphine conditioned place-preference (CPP) more readily than morphine-treated animals housed with drug-naïve animals (referred to as morphine cage-mates). However, the molecular mechanisms underlying these effects are still elusive. METHODS: Mice received repeated morphine or saline while housed as saline only, morphine only, or cage-mates. Then, they were examined for the expression levels of D1 dopamine receptor (D1DR), D2 dopamine receptor (D2DR), dopamine transporter (DAT), oxytocin, and Arginine-vasopressin (AVP) in the striatum using qPCR. Additionally, we examined the effects of the AVP-V1b receptor antagonist, SSR149415, on the acquisition of morphine conditioned place-preference (CPP). RESULTS: Increased striatal expression of D1DR and AVP was observed in morphine only animals, but not morphine cage-mates. No significant effects were observed on the striatal expression of D2DR, DAT, or oxytocin. Antagonizing the AVP-V1b receptors decreased the acquisition of morphine CPP in the morphine only mice, but did not alter the acquisition of morphine CPP in the morphine cage-mate mice. CONCLUSIONS: Housing with drug-naïve animals protects against the increase in striatal expression of D1DR and AVP elicited by morphine exposure. Moreover, our studies suggest that the protective effect of housing with drug-naïve animals on the acquisition of morphine reward might be, at least partially, mediated by AVP.
Asunto(s)
Arginina Vasopresina/biosíntesis , Vivienda para Animales , Morfina/administración & dosificación , Receptores de Dopamina D1/biosíntesis , Recompensa , Conducta Social , Animales , Arginina Vasopresina/antagonistas & inhibidores , Condicionamiento Clásico/efectos de los fármacos , Condicionamiento Clásico/fisiología , Relación Dosis-Respuesta a Droga , Masculino , Ratones , Ratones Endogámicos C57BL , Receptores de Dopamina D1/antagonistas & inhibidoresRESUMEN
Corticotroph cells from the anterior pituitary are an integral component of the hypothalamic-pituitary-adrenal (HPA) axis, which governs the neuroendocrine response to stress. Corticotrophs are electrically excitable and fire spontaneous single-spike action potentials and also display secretagogue-induced bursting behavior. The HPA axis function is dependent on effective negative feedback in which elevated plasma glucocorticoids result in inhibition at the level of both the pituitary and the hypothalamus. In this study, we have used an electrophysiological approach coupled with mathematical modeling to investigate the regulation of spontaneous and CRH/arginine vasopressin-induced activity of corticotrophs by glucocorticoids. We reveal that pretreatment of corticotrophs with 100 nM corticosterone (CORT; 90 and 150 min) reduces spontaneous activity and prevents a transition from spiking to bursting after CRH/arginine vasopressin stimulation. In addition, previous studies have identified a role for large-conductance calcium- and voltage-activated potassium (BK) channels in the generation of secretagogue-induced bursting in corticotrophs. Using the dynamic clamp technique, we demonstrated that CRH-induced bursting can be switched to spiking by subtracting a fast BK current, whereas the addition of a fast BK current can induce bursting in CORT-treated cells. In addition, recordings from BK knockout mice (BK(-/-)) revealed that CORT can also inhibit excitability through BK-independent mechanisms to control spike frequency. Thus, we have established that glucocorticoids can modulate multiple properties of corticotroph electrical excitability through both BK-dependent and BK-independent mechanisms.
Asunto(s)
Arginina Vasopresina/farmacología , Corticotrofos/efectos de los fármacos , Hormona Liberadora de Corticotropina/farmacología , Potenciales Evocados/efectos de los fármacos , Glucocorticoides/farmacología , Adenohipófisis/efectos de los fármacos , Animales , Arginina Vasopresina/antagonistas & inhibidores , Células Cultivadas , Corticotrofos/fisiología , Hormona Liberadora de Corticotropina/antagonistas & inhibidores , Regulación hacia Abajo/efectos de los fármacos , Regulación hacia Abajo/genética , Potenciales Evocados/genética , Subunidades alfa de los Canales de Potasio de Gran Conductancia Activados por Calcio/genética , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Adenohipófisis/citología , Adenohipófisis/fisiologíaRESUMEN
Polyuria related to pharmacologic α2-adrenoreceptor agonism has been well described in vitro and in animal models and is thought to be the result of functional antagonism of arginine vasopressin. Despite its widespread use as a sedative and anesthetic adjunct, very few reports of dexmedetomidine-related polyuria in humans exist in the literature. We present the first description of a pediatric patient manifesting polyuria and hypernatremia in association with dexmedetomidine infusion for posterior spinal fusion.
Asunto(s)
Dexmedetomidina/efectos adversos , Hipnóticos y Sedantes/efectos adversos , Poliuria/inducido químicamente , Animales , Arginina Vasopresina/antagonistas & inhibidores , Niño , Femenino , Humanos , Hipernatremia/inducido químicamente , Fusión VertebralRESUMEN
Lithium still retains its critical position in the treatment of bipolar disorder by virtue of its ability to prevent suicidal tendencies. However, chronic use of lithium is often limited by the development of nephrogenic diabetes insipidus (NDI), a debilitating condition. Lithium-induced NDI is due to resistance of the kidney to arginine vasopressin (AVP), leading to polyuria, natriuresis and kaliuresis. Purinergic signalling mediated by extracellular nucleotides (ATP/UTP), acting via P2Y receptors, opposes the action of AVP on renal collecting duct (CD) by decreasing the cellular cAMP and thus AQP2 protein levels. Taking a cue from this phenomenon, we discovered the potential involvement of ATP/UTP-activated P2Y2 receptor in lithium-induced NDI in rats and showed that P2Y2 receptor knockout mice are significantly resistant to Li-induced polyuria, natriuresis and kaliuresis. Extension of these studies revealed that ADP-activated P2Y12 receptor is expressed in the kidney, and its irreversible blockade by the administration of clopidogrel bisulphate (Plavix(®)) ameliorates Li-induced NDI in rodents. Parallel in vitro studies showed that P2Y12 receptor blockade by the reversible antagonist PSB-0739 sensitizes CD to the action of AVP. Thus, our studies unravelled the potential beneficial effects of targeting P2Y2 or P2Y12 receptors to counter AVP resistance in lithium-induced NDI. If established in further studies, our findings may pave the way for the development of better and safer methods for the treatment of NDI by bringing a paradigm shift in the approach from the current therapies that predominantly counter the anti-AVP effects to those that enhance the sensitivity of the kidney to AVP action.
Asunto(s)
Acuaporinas/metabolismo , Arginina Vasopresina/antagonistas & inhibidores , Diabetes Insípida Nefrogénica/terapia , Litio/toxicidad , Receptores Purinérgicos P2Y2/metabolismo , Animales , Arginina Vasopresina/metabolismo , Diabetes Insípida Nefrogénica/inducido químicamente , Humanos , Natriuresis/fisiologíaRESUMEN
The central melanocortin (MC) system has been widely studied for its effects on food intake and sexual behavior. However, the MC system, and more specifically the MC4 receptor (MC4R), also interacts with neurochemical systems that regulate socioemotional behaviors, including oxytocin (OT) and dopamine. In monogamous prairie voles, OT and dopamine interact to promote partner preference formation, a laboratory measure of an enduring social bond between mates. Here we investigated the effects of MC receptor activation on partner preference formation in prairie voles, as well as the interaction between the MC and OT systems during this process. Peripheral administration of the brain penetrant MC3/4R receptor peptide agonist, Melanotan II (MTII), and the highly selective, small-molecule MC4R agonist, Pf-446687, enhanced partner preference formation in the prairie vole, but not in the non-monogamous meadow vole. MTII-induced partner preferences were enduring, as they were present 1 week after drug manipulation. The prosocial effects of MCR agonists may be mediated, in part, through modulation of OT, as coadministration of an OT receptor antagonist prevented MTII-induced partner preferences. MTII also selectively activated hypothalamic OT neurons and potentiated central OT release. As OT has been shown to enhance some aspects of social cognition in humans, our data suggest that the MC4R may be a viable therapeutic target for enhancing social function in psychiatric disorders, including autism spectrum disorders and schizophrenia, potentially through activation of the OT system.
Asunto(s)
Oxitocina/metabolismo , Apareamiento , Receptores de Melanocortina/agonistas , Conducta Sexual Animal/efectos de los fármacos , alfa-MSH/análogos & derivados , Animales , Arginina Vasopresina/antagonistas & inhibidores , Arginina Vasopresina/metabolismo , Arvicolinae , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Relación Dosis-Respuesta a Droga , Proteína 1 de la Respuesta de Crecimiento Precoz/metabolismo , Femenino , Masculino , Oxitocina/farmacología , Péptidos Cíclicos/farmacología , Piperidinas/farmacología , Pirrolidinas/farmacología , Receptores de Melanocortina/genética , Receptores de Melanocortina/metabolismo , Receptores de Oxitocina/agonistas , Receptores de Oxitocina/genética , Receptores de Oxitocina/metabolismo , Caracteres Sexuales , Vasotocina/análogos & derivados , Vasotocina/farmacología , alfa-MSH/farmacologíaRESUMEN
Increased neurohormonal activation is a key feature of heart failure (HF). Copeptin is a surrogate marker for proarginine vasopressin and the prognostic value of copeptin has been reported for multiple disease states of both nonvascular and cardiovascular etiology. Elevated plasma copeptin in HF has been associated with adverse outcomes such as increased mortality, risk of hospitalization and correlates with the severity of HF. Copeptin may add prognostic information to already established predictors such as clinical variables and natriuretic peptides in HF. In addition, copeptin has been found to be a superior marker when compared with BNP and NT-proBNP in HF patients discharged after hospitalization caused by HF or myocardial infarction (MI). The optimal use of copeptin in HF remains unresolved and future appropriately sized and randomized trials must determine the role of copeptin in HF as a marker of adverse outcomes, risk stratification or as a target in biomarker-guided therapy with arginine vasopressin-antagonists in individualized patient treatment and everyday clinical practice.
Asunto(s)
Glicopéptidos/sangre , Insuficiencia Cardíaca/sangre , Medicina de Precisión/métodos , Arginina Vasopresina/antagonistas & inhibidores , Biomarcadores/sangre , Insuficiencia Cardíaca/tratamiento farmacológico , Insuficiencia Cardíaca/mortalidad , Humanos , Infarto del Miocardio/sangre , Infarto del Miocardio/tratamiento farmacológico , Infarto del Miocardio/mortalidad , Péptido Natriurético Encefálico/sangre , Fragmentos de Péptidos/sangre , Índice de Severidad de la EnfermedadRESUMEN
Synthesis of three clinical candidates for medicines, a human urate transporter-1 inhibitor, an arginine vasopressin antagonist, and a 17ß-hydroxysteroid dehydrogenase type-3 inhibitor, is described. These compounds were synthesized via construction of their 3,4-dihydro-2H-benzo[b][1,4]oxazine, dibenzodiazepine, and dibenzazocine skeletons, respectively, using the reductive ring-expansion reaction of the corresponding bicyclic or tricyclic oximes with diisobutylaluminum hydride.
Asunto(s)
17-Hidroxiesteroide Deshidrogenasas/antagonistas & inhibidores , Arginina Vasopresina/antagonistas & inhibidores , Inhibidores Enzimáticos/síntesis química , Transportadores de Anión Orgánico/antagonistas & inhibidores , Proteínas de Transporte de Catión Orgánico/antagonistas & inhibidores , Oximas/química , Técnicas de Química Sintética , Dibenzazepinas/química , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Humanos , Oximas/farmacologíaAsunto(s)
Antagonistas de los Receptores de Hormonas Antidiuréticas , Arginina Vasopresina/antagonistas & inhibidores , Diseño de Fármacos , Insuficiencia Cardíaca/tratamiento farmacológico , Enfermedad Aguda , Animales , Arginina Vasopresina/metabolismo , Ensayos Clínicos como Asunto , Insuficiencia Cardíaca/fisiopatología , Humanos , Hiponatremia/prevención & control , Pronóstico , Sodio/sangre , Investigación Biomédica TraslacionalRESUMEN
Heart failure is a growing health and economic problem in America, and outcomes continue to remain dismal, particularly for those presenting with acute heart failure syndrome (AHFS). In theory, arginine vasopressin antagonists (VRAs) could be useful in both acute and chronic heart failure, depending on which vasopressin receptor is targeted. Most studies of VRAs in heart failure have focused on V2 receptor antagonism, and to a lesser extent on combined V1a/V2 antagonism, due to the availability of appropriate agents and the unmet need of improving outcomes in AHFS. These agents are particularly attractive as adjunctive or alterative agents in AHFS because of their ability to produce a substantial diuresis without some of the drawbacks intrinsic to loop diuretics. While VRAs have been shown to ameliorate signs and symptoms of congestion when added to standard care, the largest trial of these agents showed no improvement in long-term morbidity, mortality, or hospitalization rates when added to standard care. This article reviews the mechanism of action of VRAs, the relevant clinical trials data, and current recommendations for clinical use, and suggests future directions for study of these agents in patients with heart failure.
Asunto(s)
Fármacos Antidiuréticos/uso terapéutico , Antagonistas de los Receptores de Hormonas Antidiuréticas , Insuficiencia Cardíaca/tratamiento farmacológico , Fármacos Antidiuréticos/efectos adversos , Arginina Vasopresina/antagonistas & inhibidores , Benzazepinas/uso terapéutico , Antagonistas de Hormonas/efectos adversos , Antagonistas de Hormonas/uso terapéutico , Humanos , TolvaptánRESUMEN
Atrial natriuretic peptide (ANP) is known to influence NaCl transport in the medullary thick ascending limbs (MAL), where the largest NaCl reabsorption occurs among distal nephron segments in response to arginine vasopressin (AVP). In the present study, we investigated the effect of ANP on bicarbonate (HCO3 (-)) transport in the MAL using an isolated tubule perfusion technique. The HCO3 (-) concentration was measured using free-flow ultramicro-fluorometer. We first observed basal HCO3 (-) reabsorption in both long- and short-looped MALs (lMALs, and sMALs, respectively). AVP inhibited HCO3 (-) reabsorption in both lMALs and sMALs, whereas ANP did not change HCO3 (-) transport. However, in the presence of AVP, ANP restored the HCO3 (-) reabsorption inhibited by AVP both in lMAL and sMAL. The effects of ANP on HCO3 (-) transport was mimicked by cyclic GMP. The mRNA expression level of the vasopressin V2 receptor in lMALs was significantly higher than in sMALs, whereas expression of the V1a receptor was unchanged. In summary, AVP inhibits HCO3 (-) transport, and ANP counteracts the action of AVP on HCO3 (-) transport both in lMALs and sMALs.
Asunto(s)
Arginina Vasopresina/farmacología , Factor Natriurético Atrial/farmacología , Bicarbonatos/metabolismo , Médula Renal/efectos de los fármacos , Animales , Arginina Vasopresina/antagonistas & inhibidores , GMP Cíclico/farmacología , Expresión Génica , Transporte Iónico/efectos de los fármacos , Médula Renal/metabolismo , Masculino , Perfusión , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de Vasopresinas/genética , Receptores de Vasopresinas/metabolismo , Reología , Técnicas de Cultivo de TejidosRESUMEN
Hypercapnia (HC) improves systemic oxygen delivery (DO2) and microvascular hemoglobin oxygenation of the mucosa (µHbO2). Simultaneously, HC increases plasma levels of vasopressin. Although vasopressin is generally regarded a potent vasoconstrictor particularly in the splanchnic region, its effects on splanchnic microcirculation during HC is unclear. The aim of this study was to evaluate the role of endogenous vasopressin on gastric mucosal oxygenation and hemodynamic variables during physiological (normocapnia) and hypercapnic conditions. Five dogs were repeatedly anesthetized to study the effect of vasopressin V(1A) receptor blockade ([Pmp¹,Tyr(Me)²]-Arg8-Vasopressin, 35â µg/kg) on hemodynamic variables and µHbO2 during normocapnia or HC (end-tidal CO2 70â mmHg). In a control group, animals were subjected to HC alone. µHbO2 was measured by reflectance spectrophotometry, systemic DO2 was calculated from intermittent blood gas analysis, and cardiac output was measured by transpulmonary thermodilution. Data are presented as mean±s.e.m. for n=5 animals. During HC alone, DO2 increased from 12±1 to 16±1âml/kg per min and µHbO2 from 70±4 to 80±2%. By contrast, additional vasopressin V(1A) receptor blockade abolished the increase in µHbO2 (80±2 vs. 69±2%) without altering the increase in DO2 (16±1 vs. 19±2â ml/kg per min). Vasopressin V1A receptor blockade (VB) during normocapnia neither affected DO2 (13±1 vs. 14±1 âml/kg per min) nor µHbO2 (75±3 vs. 71±5%). Vasopressin V(1A) receptor blockade abolished the increase in µHbO2 during HC independent of DO2. Thus, in contrast to its generally vasoconstrictive properties, the vasopressin V1A receptors seem to mediate the increase in gastric microcirculatory mucosal oxygenation induced by acute HC.
Asunto(s)
Arginina Vasopresina/metabolismo , Mucosa Gástrica/irrigación sanguínea , Hipercapnia/metabolismo , Receptores de Vasopresinas/metabolismo , Flujo Sanguíneo Regional , Transducción de Señal , Regulación hacia Arriba , Acidosis/etiología , Animales , Animales Endogámicos , Antagonistas de los Receptores de Hormonas Antidiuréticas , Arginina Vasopresina/análogos & derivados , Arginina Vasopresina/antagonistas & inhibidores , Arginina Vasopresina/uso terapéutico , Gasto Cardíaco/efectos de los fármacos , Perros , Femenino , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/metabolismo , Hemodinámica/efectos de los fármacos , Hipercapnia/sangre , Hipercapnia/tratamiento farmacológico , Hipercapnia/fisiopatología , Microvasos/efectos de los fármacos , Microvasos/fisiopatología , Oxígeno/sangre , Oxihemoglobinas/análisis , Distribución Aleatoria , Flujo Sanguíneo Regional/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Regulación hacia Arriba/efectos de los fármacos , Vasodilatadores/uso terapéuticoRESUMEN
INTRODUCTION: Hyperglycemia is a principal characteristic of diabetes and influences many cellular functions. Diabetic nephropathy is characterized by glomerular mesangial expansion which could result from increased mesangial cell extracellular matrix synthesis induced by hyperglycemia. METHODS: To investigate whether the physiological functions of mesangial cells are altered in a diabetic environment, we evaluated the effect of high extracellular glucose concentration on thymidine/leucine incorporation, hyperplasia/hypertrophy, and type IV collagen synthesis, induced by vasopressin (AVP), in cultured rat mesangial cells. RESULTS: The exposure of mesangial cells to a high glucose concentration (30 mM) significantly reduced AVP-induced thymidine incorporation and hyperplasia compared with normal glucose (10 mM). By contrast, treatment of mesangial cells with AVP in the presence of high extracellular glucose significantly increased leucine incorporation, hypertrophy, and type IV collagen synthesis compared with those at normal glucose levels. The administration of staurosporine, a protein kinase C inhibitor, reversed these effects of high-glucose conditions. Furthermore, the nonpeptide AVP V(1A) receptor-selective antagonists potently inhibited these AVP-induced physiological responses in mesangial cells cultured in high-glucose conditions. CONCLUSIONS: These results demonstrate that high glucose suppresses mesangial cell proliferation but enhances hypertrophy and type IV collagen synthesis induced by AVP. This increased mesangial cell hypertrophy and extracellular matrix synthesis may play a crucial role in the glomerular mesangial expansion common to diabetic nephropathy.
Asunto(s)
Fármacos Antidiuréticos/farmacología , Arginina Vasopresina/farmacología , Hiperglucemia/fisiopatología , Células Mesangiales/efectos de los fármacos , Células Mesangiales/fisiología , Animales , Arginina Vasopresina/antagonistas & inhibidores , Células Cultivadas , Colágeno Tipo IV/biosíntesis , Nefropatías Diabéticas/tratamiento farmacológico , Nefropatías Diabéticas/metabolismo , Nefropatías Diabéticas/prevención & control , Inhibidores Enzimáticos/farmacología , Mesangio Glomerular/metabolismo , Hiperplasia/tratamiento farmacológico , Hiperplasia/fisiopatología , Hipertrofia/tratamiento farmacológico , Hipertrofia/fisiopatología , Células Mesangiales/patología , Ratas , Ratas Wistar , Estaurosporina/farmacologíaRESUMEN
Hyponatremia, a common electrolyte abnormality in oncology practice, may be a negative prognostic factor in cancer patients based on a systematic analysis of published studies. The largest body of evidence comes from small-cell lung cancer (SCLC), for which hyponatremia was identified as an independent risk factor for poor outcome in six of 13 studies. Hyponatremia in the cancer patient is usually caused by the syndrome of inappropriate antidiuretic hormone (SIADH), which develops more frequently with SCLC than with other malignancies. SIADH may be driven by ectopic production of arginine vasopressin (AVP) by tumors or by effects of anticancer and palliative medications on AVP production or action. Other factors may cause hypovolemic hyponatremia, including diarrhea and vomiting caused by cancer therapy. Hyponatremia may be detected on routine laboratory testing before or during cancer treatment or may be suggested by the presence of mostly neurological symptoms. Treatment depends on several factors, including symptom severity, onset timing, and extracellular volume status. Appropriate diagnosis is important because treatment differs by etiology, and choosing the wrong approach can worsen the electrolyte abnormality. When hyponatremia is caused by SIADH, hypertonic saline is indicated for acute, symptomatic cases, whereas fluid restriction is recommended to achieve a slower rate of correction for chronic asymptomatic hyponatremia. Pharmacological therapy may be necessary when fluid restriction is insufficient. The orally active, selective AVP receptor 2 (V(2))-receptor antagonist tolvaptan provides a mechanism-based option for correcting hyponatremia caused by SIADH or other conditions with inappropriate AVP elevations. By blocking AVP effects in the renal collecting duct, tolvaptan promotes aquaresis, leading to a controlled increase in serum sodium levels.
Asunto(s)
Manejo de la Enfermedad , Hiponatremia/diagnóstico , Hiponatremia/terapia , Neoplasias/fisiopatología , Antagonistas de los Receptores de Hormonas Antidiuréticas , Arginina Vasopresina/antagonistas & inhibidores , Arginina Vasopresina/efectos de los fármacos , Arginina Vasopresina/metabolismo , Benzazepinas/farmacología , Humanos , Hiponatremia/etiología , Hipovolemia/complicaciones , Hipovolemia/diagnóstico , Hipovolemia/terapia , Síndrome de Secreción Inadecuada de ADH/complicaciones , Síndrome de Secreción Inadecuada de ADH/fisiopatología , Síndrome de Secreción Inadecuada de ADH/terapia , Neoplasias/complicaciones , Neoplasias/terapia , Receptores de Vasopresinas/metabolismo , Factores de Riesgo , Sodio/sangre , TolvaptánRESUMEN
We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V(1a), V(1b) and V(2) receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT). In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents. We also present our recent findings on the design of fluorescent ligands for V(1b) receptor localisation and for OT receptor dimerisation. We note the exciting discoveries regarding two novel naturally occurring analogues of OT. Recent reports of a selective VP V(1a) agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field. To date, only two nonpeptides, the V(2) /V(1a) antagonist, conivaptan and the V(2) antagonist tolvaptan have received Food and Drug Administration approval for clinical use. The development of nonpeptide AVP V(1a), V(1b) and V(2) antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer. A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clinical trial for the prevention of premature labour. A number of the nonpeptide ligands that were not successful in clinical trials are proving to be valuable as research tools. Peptide agonists and antagonists continue to be very widely used as research tools in this field. In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, especially with regard to receptor selectivity and species differences.
Asunto(s)
Arginina Vasopresina/análogos & derivados , Arginina Vasopresina/uso terapéutico , Oxitocina/análogos & derivados , Oxitocina/uso terapéutico , Animales , Antagonistas de los Receptores de Hormonas Antidiuréticas , Arginina Vasopresina/agonistas , Arginina Vasopresina/antagonistas & inhibidores , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/estadística & datos numéricos , Humanos , Oxitocina/agonistas , Oxitocina/antagonistas & inhibidores , Receptores de Oxitocina/agonistas , Receptores de Oxitocina/antagonistas & inhibidores , Receptores de Vasopresinas/agonistas , Relación Estructura-ActividadRESUMEN
Anemia is an independent predictor of mortality in congestive heart failure patients. Recent studies have recognized that dilutional anemia is highly prevalent in this population. However, the implications for treatment have not been comprehensively elucidated. In this regard, arginine-vasopressin antagonists, by increasing aquaresis, may be an attractive treatment option. Nevertheless, only indirect evidence supports the hypothesis that arginine-vasopressin antagonists may be useful in the treatment of congestive heart failure anemia. Therefore, future clinical research should explore the role of arginine-vasopressin pathway activation in determining dilutional anemia and, ultimately, assess it as a therapeutic target.